FDA's Guide: How We Peek into Your Lipstick Lab Records
Published Date: 1/22/2026
Notice
Summary
The FDA just dropped a draft guide to help cosmetic companies understand how the agency can check their product records. If you make or sell cosmetics, this guide explains what info the FDA might ask for and how the process works. You’ve got until March 23, 2026, to share your thoughts before the FDA finalizes the rules—no extra costs yet, just clear steps ahead!
Analyzed Economic Effects
4 provisions identified: 1 benefits, 3 costs, 0 mixed.
FDA can copy records if SAHCODH suspected
Under section 610 (21 U.S.C. 364f), if FDA reasonably believes a cosmetic (or an ingredient) is likely adulterated and presents a threat of serious adverse health consequences or death (SAHCODH), FDA may access and copy certain records. The draft guidance explains how FDA applies that authority and what records may be copied.
Inspection authority extended to manufacturer records
Section 704(a)(1) of the FD&C Act, as amended by MoCRA (section 3504), extends FDA's inspectional authority to all records and information described in sections 605 and 610 from facilities that manufacture and process cosmetic products. The draft guidance discusses how that expanded inspection authority is applied.
FDA access to adverse event records
If you make or sell cosmetics, FDA can access adverse event records during an inspection under section 605 (21 U.S.C. 364a) and section 704 of the FD&C Act. The draft guidance explains FDA's criteria, process, and expectations for that access.
Draft guidance available — comment deadline
The FDA released a draft guidance titled "FDA Records Access Authority for Cosmetics: Guidance for Industry" and is asking for comments. You may submit electronic or written comments by March 23, 2026; the guidance is not binding and explains FDA's current thinking on criteria, process, and expectations.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-06478 — Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY
The FDA has officially set the review period for VYLOY, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind VYLOY, giving them a chance to extend their patent protection and potentially boost profits. If anyone thinks the dates are wrong or wants to challenge the company’s review speed, they must act by June 2 or September 30, 2026.
2026-06481 — Determination of Regulatory Review Period for Purposes of Patent Extension; HYMPAVZI
The FDA has set the official review period for HYMPAVZI, a new human biological product, so its patent holder can apply for extra patent time. This affects the company behind HYMPAVZI and anyone interested in patent extensions. If you think the dates are wrong or want to challenge the company’s diligence, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06480 — Determination of Regulatory Review Period for Purposes of Patent Extension; EMRELIS
The FDA has officially set the review period for EMRELIS, a medicine patent, so the patent owner can apply for extra protection time. If anyone thinks the dates are wrong, they have until June 2, 2026, to speak up. Also, people can challenge whether the patent owner was diligent during the review by September 30, 2026. This affects patent holders and could impact how long they keep exclusive rights to their product.
2026-06479 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENFLONSIA
The FDA has set the official review period for ENFLONSIA, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind ENFLONSIA and anyone interested in patent rules. If you think the dates are wrong or want to challenge the company’s review speed, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06477 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENCELTO
The FDA has officially set the review period for ENCELTO, a medicine patent, so the company can apply to extend its patent protection. This affects the drug maker by potentially giving them more time to exclusively sell ENCELTO, which can mean more money. If anyone thinks the dates are wrong or the company wasn’t diligent, they have until June 2 or September 30, 2026, to speak up.
2026-06483 — Determination of Regulatory Review Period for Purposes of Patent Extension; INJECTAFER
The FDA has officially set the review period for INJECTAFER, a drug patent up for extension. This means the company can apply to extend their patent protection, potentially keeping their exclusive rights longer and impacting competition and pricing. If anyone thinks the dates are wrong or the company wasn’t diligent, they can speak up by June 2 or September 30, 2026.
Previous / Next Documents
Previous: 2026-01158 — Medical Review Board; Membership
The Department of Transportation is looking for new members to join the Medical Review Board, which gives expert medical advice about truck driver health rules. If you or someone you know works in medicine and wants to help shape safety standards for commercial drivers, now’s the time to apply! Nominations are due by February 23, 2026, and there’s no cost to join—just a chance to make a big impact.
Next: 2026-01160 — Procurement List; Additions
Starting February 1, 2026, new services will be added to the government’s Procurement List, meaning federal agencies must buy these services from nonprofit groups that employ people who are blind or have severe disabilities. This change helps support these nonprofits without adding extra paperwork or costs. It’s a win-win for the government and amazing workers making a difference!
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in